Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOTECH Net Asset Value 2016

Oct 7, 2016

9301_rns_2016-10-07_7b38fb17-5130-4403-9b0c-7c8340b30a25.html

Net Asset Value

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

THE BIOTECH GROWTH TRUST PLC - Compliance with Market Abuse Regulation

PR Newswire

London, October 7

The Biotech Growth Trust PLC (“the Company”)

Compliance with Market Abuse Regulation

7 October 2016

The Company confirms that:

a)         all inside information which the Directors and Company may have had has been notified to a Regulated Information Service (“RIS”);

b)         the Company’s net asset value per share is calculated and announced through a RIS on a daily basis;

c)         the Company has no reason to believe that there will be any material difference between the net asset value per share as at close of business on 30 September 2016, which was announced on 3 October 2016, and the financial information to be published in the announcement of its results for the half year ended 30 September 2016.

Further to an announcement made on 3 October 2016 the Company is, therefore, not prohibited from dealing in its own securities during the closed period, as defined by the Market Abuse Regulation, which will end on the date of the publication of its results for the half year ended 30 September 2016, expected to be on or after 9 November 2016. 

-ENDS-

For further information please contact:

Victoria Hale     Frostrow Capital LLP     020 3 170 8732